NEO - NeoGenomics, Inc.
NEXT EARNINGS:
May 5, 2026
EPS Est: $0.01
|
Rev Est: $184.5M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Market Cap:
249.72M
Volume:
1,776,931
Avg Volume:
1,872,851
52 Week Range:
4.72-13.74
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Beta:
1.58
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
2,200
IPO Date:
2004-03-16
EPS (TTM):
-4.20
P/E Ratio:
-5.30
Revenue (TTM):
727.33M
Total Assets:
1.36B
Total Debt:
472.28M
Cash & Equiv:
159.62M
Rev Growth (5Y):
10.1%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-5.2%
Debt/Equity:
0.67
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-17 | $0.06 | $0.04 | +50.0% | $190.2M | $185.2M | +2.7% |
| 2025-10-28 | $0.03 | $0.02 | +50.0% | $187.8M | $188.2M | -0.2% |
| 2025-07-29 | $0.03 | $0.03 | 0.0% | $181.3M | $183.9M | -1.4% |
| 2025-04-29 | $-0.08 | $-0.02 | -300.0% | $168.0M | $182.9M | -8.1% |
| 2025-02-18 | $0.04 | $0.03 | +33.3% | $172.0M | $172.6M | -0.3% |
| 2024-11-05 | $0.05 | $0.01 | +316.7% | $167.8M | $173.1M | -3.0% |
| 2024-07-29 | $0.03 | $0.00 | +880.4% | $164.5M | $166.6M | -1.3% |
| 2024-04-30 | $-0.02 | $-0.01 | -59.2% | $156.2M | $162.2M | -3.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 727.33M | 660.57M | 591.64M | 509.73M | 484.33M | 444.45M | 408.83M | 276.74M | 240.25M | 244.08M | 99.80M | 87.07M |
| Net Income | (108.03M) | (78.73M) | (87.97M) | (144.25M) | (8.35M) | 4.17M | 8.01M | 2.64M | (396,000) | (6.14M) | (2.54M) | 1.13M |
| EPS | -4.20 | -3.10 | -3.50 | -5.80 | -0.35 | 0.19 | 0.40 | 0.14 | -0.03 | -0.39 | -0.21 | 0.10 |
| Total Assets | 1.36B | 1.64B | 1.68B | 1.74B | 1.87B | 988.33M | 709.51M | 505.01M | 343.34M | 337.12M | 367.95M | 81.11M |
| Total Debt | 472.28M | 605.33M | 611.68M | 610.93M | 612.79M | 218.22M | 132.88M | 112.30M | 105.42M | 106.17M | 71.38M | 8.48M |
| Cash & Equivalents | 159.62M | 367.01M | 342.49M | 263.18M | 316.83M | 228.71M | 173.02M | 9.81M | 12.82M | 12.53M | 23.42M | 33.69M |
| Operating Cash Flow | 5.23M | 7.02M | (1.95M) | (65.99M) | (26.72M) | 1.46M | 23.37M | 44.79M | 18.04M | 21.48M | 6.39M | 9.45M |
| Free Cash Flow | (21.78M) | (34.04M) | (30.70M) | (96.88M) | (90.86M) | (27.64M) | 3.34M | 30.48M | 4.35M | 13.94M | 4.18M | 5.68M |
| FCF per Share | -0.85 | -1.34 | -1.22 | -3.90 | -3.79 | -1.27 | 0.17 | 1.66 | 0.27 | 0.89 | 0.35 | 0.50 |
| Book Value | 836.56M | 902.34M | 941.54M | 998.02M | 1.11B | 694.29M | 507.41M | 320.44M | 205.53M | 186.60M | 238.11M | 60.41M |
| Cash & ST Investments | 159.62M | 386.84M | 415.20M | 437.99M | 515.39M | 296.26M | 173.02M | 9.81M | 12.82M | 12.53M | 23.42M | 33.69M |
| ROC Equity | -0.13 | -0.09 | -0.09 | -0.14 | -0.01 | 0.01 | 0.02 | 0.01 | -0.00 | -0.03 | -0.01 | 0.02 |